Mirum Pharmaceuticals, Inc.
MIRM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $4 | $3 | $2 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $4 | $3 | $2 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 4.1% | 14.5% | 12.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 80.8% | 81.7% | 79.4% | 77.1% |
| EBITDA | $0 | $0 | -$0 | -$0 |
| % Margin | 6.8% | 3.3% | -3.6% | -14.8% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 2.2% | -4.6% | -13.2% | -23.9% |
| EPS Diluted | 0.05 | -0.12 | -0.3 | -0.49 |
| % Growth | 141.7% | 60% | 38.8% | – |
| Operating Cash Flow | $0 | $0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | -$0 | -$0 |